Iga Nephropathy
📧 Sign up to get email alerts when something new happens for Iga Nephropathy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-07-20Clinical Trial Results: Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy [Phase 2]
Phase 2 randomized, double-blind, placebo-controlled crossover trial of atrasentan in IgA nephropathy completed with results posted.
-
CLINICAL_TRIALS trial_result · 2026-06-04Clinical Trial Update: Atrasentan in Patients With IgA Nephropathy [Phase 3]
Phase 3 trial update for atrasentan in IgA nephropathy is active/not recruiting.
-
EMA approval · 2026-04-23EMA Authorised: Kinpeygo (budesonide, micronised) — Stada Arzneimittel AG
The European Medicines Agency authorised Kinpeygo, a budesonide, micronised formulation, for IgA nephropathy, with orphan designation, devel…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases [EARLY_Phase 1]
An early Phase 1 clinical study evaluating the safety and efficacy of GT719 universal cell injection for immune-mediated kidney diseases is …
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease [Phase 2]
Phase 2 clinical trial evaluating ADX-038 for complement-mediated kidney disease, including IgA nephropathy and C3 glomerulopathy, is curren…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition [Phase 3]
A Phase 3 clinical trial evaluating mezagitamab for adults with primary IgA nephropathy is currently recruiting to evaluate safety and effic…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: A Phase 2 Study of JADE101 in Participants With Immunoglobulin A Nephropathy [Phase 2]
A Phase 2 study of JADE101 for IgA nephropathy is listed, but the trial is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN) [Phase 1, Phase 2]
This document provides an update on the safety and tolerability of BION-1301 in healthy volunteers and adults with IgA nephropathy (IgAN) ac…
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: Efficacy and Safety of CD19 CAR-γδ T Cells in the Treatment of Relapsed/Refractory Autoimmune Nephropathy [EARLY_Phase 1]
Clinical trial update for a Phase 1 study of CD19 CAR-γδ T cells in relapsed/refractory autoimmune nephropathy, targeting membranous nephrop…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression [Phase 3]
Phase 3 clinical trial update announcing ongoing recruitment for Sefaxersen (RO7434656) in adults with high-risk primary IgA nephropathy.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
An ongoing biomarker evaluation study for IgA nephropathy and other glomerular diseases is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Monthly Dosing of Atacicept in IgAN [Phase 2]
A Phase 2 trial of atacicept for IgA nephropathy is ongoing but not currently recruiting, per Vera Therapeutics' update.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN) [Phase 2]
This clinical trial update reports a Phase 2 study of NM8074 for IgA nephropathy, which is currently not yet recruiting.
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Study of WAL0921 in Patients With Glomerular Kidney Diseases [Phase 2]
Walden Biosciences reports a Phase 2 clinical trial of WAL0921 in multiple glomerular diseases, currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease [EARLY_Phase 1]
An early-phase trial of allogeneic CD19/BCMA CAR-T therapy for B-cell–related autoimmune diseases is recruiting at The Children's Hospital o…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: A Study of Zigakibart in Adults With IgA Nephropathy [Phase 3]
A Phase 3 clinical trial update indicates Zigakibart is being studied in adults with IgA nephropathy and the study is currently active but n…
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN [Phase 3]
Phase 3 pediatric trial to assess the efficacy, pharmacokinetics, safety, and tolerability of iptacopan in children with primary IgA nephrop…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN [Phase 3]
Phase 3 pediatric trial evaluating atrasentan for efficacy, pharmacokinetics, safety and tolerability in primary IgA nephropathy; the study …
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: FXS6837 for the Treatment of IgAN Patients [Phase 2]
Phase 2 clinical trial of FXS6837 for IgA nephropathy is listed as not yet recruiting, with Shanghai Fosun Pharmaceutical as sponsor.
-
CLINICAL_TRIALS trial_result · 2026-03-30Clinical Trial Update: Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 [Phase 2]
Omeros' Phase 2 safety study of OMS721 in immunoglobulin A nephropathy, lupus nephritis, membranous nephropathy, and C3 glomerulopathy inclu…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: A Study of YKST02 in Participants With Primary IgA Nephropathy [EARLY_Phase 1]
A clinical trial update for the drug YKST02 in participants with primary IgA nephropathy; the early-phase 1 study is not yet recruiting.
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Study of ARO-CFB in Adult Healthy Volunteers [Phase 1]
Phase 1 study of ARO-CFB in healthy adult volunteers for an IgA Nephropathy program; the trial is currently active but not recruiting, spons…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: PS-002 for the Treatment of IgA Nephropathy in Adults [Phase 1, Phase 2]
This clinical trial update indicates PS-002 for immunoglobulin A nephropathy is in Phase 1/Phase 2 and currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: IgA Nephropathy Insights From Treatment Experience Among Patients Receiving Iptacopan and/or Atrasentan Using Primary Data Collection
A clinical trial update describing primary-data collection on treatment experience for IgA nephropathy patients treated with iptacopan and/o…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: Study of Ravulizumab in Pediatric Participants With Primary IgAN [Phase 3]
Phase 3 clinical trial update indicates Ravulizumab is being studied in pediatric participants with primary IgA nephropathy, including IgA v…